“In November 2022, a study revealed that blood pressure drugs that stimulate type 2 and 4 angiotensin II receptors in the brain were associated with lower rates of dementia among new users of ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...

But up to half of all dementia cases might be preventable, and scientists have identified over a dozen modifiable risk factors that contribute to dementia risk, including obesity, type 2 diabetes ...

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new study suggests. Researchers found these medications show promise in ...

has found that its “miracle” weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues. What Happened: A study ...

New study suggests that Novo Nordisk’s Ozempic may lower dementia risk and nicotine use. Meanwhile, UnitedHealth Group’s cyberattack woes aren’t over yet.

An analysis of over 100,000 medical records found that Ozempic users had a far lower dementia risk than those that took other diabetes drugs.

Two new studies published in JAMA Neurology reveal that GLP-1 receptor agonists, like Ozempic and Trulicity, may significantly reduce the risk of dementia, particularly in individuals with type 2 ...